Drug Trial Radar · NCT06898450
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
134
Planned (sponsor's estimate)
Start
Mar 31, 2025
Primary completion
Oct 2031
Study completion Dec 2031
Sponsor
- Lead sponsor
- Nimbus Wadjet, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials
- First posted
- Mar 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? What kind of effects does NDI-219216 have on the body? Does NDI-219216 have any impact on tumor size? Participants will: Take NDI-219216 every day by mouth. Visit the clinic 6 times during Cycle 1, 2 times during Cycle 2, once a month thereafter for checkups and tests while on the study, then one time for an end of treatment visit. After the End of Study, a follow up will occur but can be done on the phone. Keep a diary of their tablet consumption and symptoms experienced.
Conditions
- Advanced Solid Tumors Cancer
- MSI-H Cancer
Interventions
NDI-219216Drug
NDI-219216 is a highly selective small molecule inhibitor of WRN helicase activity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A Primary Objective: Incidence of dose limiting toxicities (DLTs)Time frame: The first 21 days of Cycle 1 (Cycle 1 is 28 days).
- Part A Primary Outcome: • Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), according to NCI CTCAE v5.0Time frame: From first dose of study drug until 30 days after last dose of study drug; up to approximately 11-12 months. Each Cycle is 28 days.
- Part A Primary Outcome: Incidence and severity of Treatment Emergent Adverse Events (TEAEs) and Treatment Related Adverse Events (TRAEs) as assessed by the InvestigatorTime frame: From first dose of study drug until 30 days after last dose of study drug; up to approximately 11-12 months. Each Cycle is 28 days.
- Part B Primary Objective: Overall Response Rate (ORR) per RECIST v1.1.Time frame: From start of study treatment until end of follow-up, up to approximately 18 months. Each Cycle is 28 days.
- Part B Primary Outcome: Duration of Response (DOR) per RECIST v1.1Time frame: From the time of first occurrence of a documented response until the time of documented disease progression or death from any cause, whichever occurs first; up to approximately 18 months. Each Cycle is 28 days.
- Part B Primary Outcome: Incidence and severity of AEs according to NCI CTCAE v5.0.Time frame: From first dose of study drug until 30 days after last dose of study drug; up to approximately 18 months. Each Cycle is 28 days.
- Part C Primary Objective: Overall Response Rate (ORR) per RECIST v1.1.Time frame: From start of study treatment until end of follow-up, up to approximately 17 months. Each Cycle is 28 days.
- Part C Primary Outcome: Duration of Response (DOR) per RECIST v1.1.Time frame: From the time of first occurrence of a documented response until the time of documented disease progression or death from any cause, whichever occurs first, up to approximately 17 months. Each Cycle is 28 days.
Locations
22 sites in 8 countries. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
University of Chicago Medicine
Chicago, Illinois · Recruiting
University of Louisville James Graham Brown Cancer Center
Louisville, Kentucky · Recruiting
Cayuga Cancer Center
Ithaca, New York · Terminated
Levine Cancer Center
Charlotte, North Carolina · Recruiting
Atrium Health Wake Forest Baptist Center
Winston-Salem, North Carolina · Recruiting
Taylor Cancer Research Center
Maumee, Ohio · Recruiting
Brown University Health
Providence, Rhode Island · Recruiting
Prisma Health Cancer Institute - Multidisciplinary Center
Greenville, South Carolina · Recruiting
University of Virginia Emily Couric Clinical Cancer Center
Charlottesville, Virginia · Recruiting
Virginia Cancer Specialists, P.C. - Fairfax
Fairfax, Virginia · Recruiting
Liverpool Hospital
Liverpool, New South Wales, Australia · Recruiting
Southern Oncology Clinical Research Unit
Bedford Park, South Australia, Australia · Recruiting
Princess Margaret Cancer Center
Toronto, Ontario, Canada · Recruiting
Hôpital Saint-Antoine - Assistance Publique-Hopitaux de Paris (AP-HP)
Paris, France · Recruiting
Centre Hospitalier Universitaire (CHU) de Poitiers
Poitiers, France · Recruiting
START Dublin
Dublin, Ireland · Recruiting
START Lisbon
Lisbon, Portugal · Recruiting
START Barcelona
Barcelona, Spain · Recruiting
Hospital Clinico San Carlos
Madrid, Spain · Recruiting
Sarah Cannon Research Institute UK
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust UK
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.